Patents by Inventor Christopher Paul Leamon

Christopher Paul Leamon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
    Publication number: 20180256736
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Application
    Filed: May 11, 2018
    Publication date: September 13, 2018
    Inventors: Iontcho Radoslavov VLAHOV, Joseph Anand REDDY, Alicia BLOOMFIELD, Ryan DORTON, Melissa NELSON, Marilynn VETZEL, Christopher Paul LEAMON
  • CONJUGATES FOR TREATING DISEASES
    Publication number: 20180228914
    Abstract: The present disclosure relates to pyrrolobenzodiazepine (PBD) prodrugs and conjugates thereof. The present disclosure also relates to pharmaceutical compositions of the conjugates described herein, methods of making and methods of using the same.
    Type: Application
    Filed: March 13, 2015
    Publication date: August 16, 2018
    Inventors: Iontcho Radoslavov VLAHOV, Christopher Paul LEAMON, Longwu QI, Yingcai WANG, Kevin Yu WANG, Ning ZOU, Albert E. FELTEN
  • CCK2R-DRUG CONJUGATES
    Publication number: 20180228909
    Abstract: The disclosure provided herein pertains to CCK2R-drug conjugates. In particular, the disclosure pertains to CCK2R-drug conjugates that target the delivery of drugs to a mammalian recipient. Also described are methods of making and using CCK2R-drug conjugates.
    Type: Application
    Filed: August 10, 2016
    Publication date: August 16, 2018
    Inventors: Garth L. PARHAM, Melissa NELSON, Marilynn VETZEL, Christina M. DIRCKSEN, Joseph Anand REDDY, Christopher Paul LEAMON, Iontcho Radoslavov VLAHOV
  • VITAMIN RECEPTOR DRUG DELIVERY CONJUGATES FOR TREATING INFLAMMATION
    Publication number: 20180221372
    Abstract: Described herein are compositions, methods, compounds, conjugates, and kits for use in targeted drug delivery using drug delivery conjugates containing hydrophilic spacer linkers for use in treating disease states caused by pathogenic cell populations, such as inflammatory cells.
    Type: Application
    Filed: November 13, 2017
    Publication date: August 9, 2018
    Inventors: Christopher Paul Leamon, Iontcho Radoslavov Vlahov, Yingjuan June Lu, Kevin Yu Wang, Fei You, Paul Joseph Kleindl, Hari Krishna R. Santhapuram
  • DRUG DELIVERY CONJUGATES OF TERTIARY AMINE CONTAINING DRUGS
    Publication number: 20180125992
    Abstract: The present disclosure relates to conjugates of tertiary amine containing drugs. The present disclosure also relates to pharmaceutical compositions of the conjugates described herein, methods of making, and methods of using the same.
    Type: Application
    Filed: October 31, 2017
    Publication date: May 10, 2018
    Inventors: Iontcho Radoslavov VLAHOV, Fei YOU, Christopher Paul LEAMON
  • DUAL DISULFIDE DRUG CONJUGATES
    Publication number: 20180110871
    Abstract: The invention described herein pertains to dual disulfide drug conjugates. In particular, the invention described herein pertains to dual disulfide drug conjugates that target the folate receptor for delivery of conjugated drugs to a mammalian recipient. Also described are methods of making and using dual disulfide drug conjugates.
    Type: Application
    Filed: April 14, 2016
    Publication date: April 26, 2018
    Inventors: Iontcho Radoslavov VLAHOV, Christopher Paul LEAMON, Fei YOU, Hanna Francesca KLEIN
  • METHODS OF TREATING CANCER WITH A PSMA LIGAND-TUBULYSIN COMPOUND
    Publication number: 20180036364
    Abstract: The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating PSMA expressing cancers with a PSMA ligand-tubulysin compound. The invention described herein also relates to methods of treating PSMA-expressing cancers with a PSMA ligand-tubulysin compound in patients where stable disease results after treatment with the PSMA ligand-tubulysin compound.
    Type: Application
    Filed: March 1, 2016
    Publication date: February 8, 2018
    Inventors: Christopher Paul LEAMON, Binh NGUYEN
  • Vitamin receptor drug delivery conjugates for treating inflammation
    Patent number: 9877965
    Abstract: Described herein are compositions, methods, compounds, conjugates, and kits for use in targeted drug delivery using drug delivery conjugates containing hydrophilic spacer linkers for use in treating disease states caused by pathogenic cell populations, such as inflammatory cells.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: January 30, 2018
    Assignee: Endocyte, Inc.
    Inventors: Christopher Paul Leamon, Iontcho Radoslavov Vlahov, Yingjuan June Lu, Kevin Yu Wang, Fei Yu, Paul Joseph Kleindl, Hari Krishna R. Santhapuram
  • DRUG DELIVERY CONJUGATES CONTAINING UNNATURAL AMINO ACIDS AND METHODS FOR USING
    Publication number: 20170360950
    Abstract: Described herein are drug delivery conjugates for targeted therapy. In particular, described herein are drug delivery conjugates that include polyvalent linkers comprising one or more unnatural amino acids that are useful for treating cancers and inflammatory diseases.
    Type: Application
    Filed: March 9, 2017
    Publication date: December 21, 2017
    Inventors: Iontcho Radoslavov VLAHOV, Christopher Paul LEAMON
  • TUBULYSIN CONJUGATE FOR USE IN TREATING CANCER
    Publication number: 20170348376
    Abstract: The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating folate receptor-expressing cancers with a folate-tubulysin conjugate. The invention described herein also relates to methods of treating folate-expressing cancers with a folate tubulysin conjugate in patients where stable disease results after treatment with the folate-tubulysin conjugate.
    Type: Application
    Filed: June 1, 2017
    Publication date: December 7, 2017
    Inventors: Christopher Paul LEAMON, Joseph Anand REDDY, Binh NGUYEN, Alicia BLOOMFIELD, Melissa NELSON, Ryan DORTON
  • VITAMIN RECEPTOR DRUG DELIVERY CONJUGATES FOR TREATING INFLAMMATION
    Publication number: 20170319585
    Abstract: Described herein are compositions, methods, compounds, conjugates, and kits for use in targeted drug delivery using drug delivery conjugates containing hydrophilic spacer linkers for use in treating disease states caused by pathogenic cell populations, such as inflammatory cells.
    Type: Application
    Filed: March 27, 2015
    Publication date: November 9, 2017
    Inventors: Christopher Paul Leamon, Iontcho Radoslavov Vlahov, Yingjuan June Lu, Kevin Yu Wang, Fei Yu, Paul Joseph Kleindl, Hari Krishna R. Santhapuram
  • METHODS OF TREATING CANCER WITH TUBULYSIN CONJUGATES
    Publication number: 20170290878
    Abstract: The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating folate receptor-expressing cancers with a folate-tubulysin conjugate. The invention described herein also relates to methods of treating folate-expressing cancers with a folate tubulysin conjugate in patients where stable disease results after treatment with the folate-tubulysin conjugate.
    Type: Application
    Filed: September 24, 2015
    Publication date: October 12, 2017
    Inventors: Christopher Paul LEAMON, Joseph Anand REDDY, Binh NGUYEN, Alicia BLOOMFIELD, Melissa NELSON, Ryan DORTON
  • Conjugates for treating diseases caused by PSMA expressing cells
    Patent number: 9782493
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: October 10, 2017
    Assignee: ENDOCYTE, INC.
    Inventors: Iontcho Radoslavov Vlahov, Joseph Anand Reddy, Alicia Bloomfield, Ryan Dorton, Melissa Nelson, Marilynn Vetzel, Christopher Paul Leamon
  • Process for preparing tubulysins
    Patent number: 9771391
    Abstract: The invention described herein pertains to processes for preparing tubulysins and derivatives thereof. The invention described herein also pertains to processes for preparing tubulysin conjugates. The invention described herein also pertains to processes for preparing intermediates for preparing tubulysin conjugates. In one step, the alpha-thiazolyl alcohol is protected with triethylsilyl chloride in the presence of imidazole in an aprotic solvent.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: September 26, 2017
    Assignee: Endocyte, Inc.
    Inventors: Iontcho Radoslavov Vlahov, Christopher Paul Leamon
  • METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES
    Publication number: 20170266303
    Abstract: Methods for treating cancers using one or more compounds comprising a folate receptor binding ligand attached to a drug via a linker are described. Methods for treating cancers using one or more compounds comprising a folate receptor binding ligand attached to a drug via a linker to target tumor associated macrophages are described.
    Type: Application
    Filed: November 24, 2015
    Publication date: September 21, 2017
    Inventors: Yingjuan J. LU, Leroy W. WHEELER, II, Philip Stewart LOW, Christopher Paul LEAMON
  • CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
    Publication number: 20170258932
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Application
    Filed: May 26, 2017
    Publication date: September 14, 2017
    Inventors: Iontcho Radoslavov VLAHOV, Joseph Anand REDDY, Alicia BLOOMFIELD, Ryan DORTON, Melissa NELSON, Marilynn VETZEL, Christopher Paul LEAMON
  • Folate Receptor Binding Conjugates of Antifolates
    Publication number: 20170246314
    Abstract: Conjugates of antifolates, releasable linkers, and drugs, and pharmaceutical compositions containing them are described. The conjugates are useful for treating diseases arising from pathogenic cell populations. Methods for treating stroll diseases are also described.
    Type: Application
    Filed: December 13, 2016
    Publication date: August 31, 2017
    Applicants: Purdue Research Foundation, Endocyte, Inc.
    Inventors: Christopher Paul Leamon, Iontcho Radoslavov Vlahov, Philip Stewart Low
  • Tubulysins and processes for preparing
    Patent number: 9745341
    Abstract: Processes are described for the preparation of tubulysins. The processes are useful for preparing predetermined mixtures of tubulysins, preparing single tubulysins from mixtures of tubulysins, and for converting one tubulysin into a different tubulysin. The tubulysins described herein are useful in treating diseases and disease states that include pathogenic cell populations.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: August 29, 2017
    Assignee: Endocyte, Inc.
    Inventors: Iontcho Radoslavov Vlahov, Christopher Paul Leamon, Kevin Yu Wang
  • Conjugates Containing Hydrophilic Spacer Linkers
    Publication number: 20170151340
    Abstract: Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and/or treating diseases and disease states caused by pathogenic cell populations.
    Type: Application
    Filed: February 13, 2017
    Publication date: June 1, 2017
    Inventors: Christopher Paul Leamon, Iontcho Radoslavov Vlahov, Hari Krishna R. Santhapuram, Paul Joseph Kleindl, Kevin Yu Wang, Fei You
  • Drug delivery conjugates containing unnatural amino acids and methods for using
    Patent number: 9662402
    Abstract: Described herein are drug delivery conjugates for targeted therapy. In particular, described herein are drug delivery conjugates that include polyvalent linkers comprising one or more unnatural amino acids that are useful for treating cancers and inflammatory diseases. The invention described herein pertains to drug delivery conjugates for targeted therapy. In particular, the invention described herein pertains to drug delivery conjugates that include polyvalent linkers comprising one or more unnatural amino acids.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: May 30, 2017
    Assignee: Endocyte, Inc.
    Inventors: Iontcho Radoslavov Vlahov, Christopher Paul Leamon